[go: up one dir, main page]

MA30352B1 - Pyridine [3,4-b] pyrazinones - Google Patents

Pyridine [3,4-b] pyrazinones

Info

Publication number
MA30352B1
MA30352B1 MA31321A MA31321A MA30352B1 MA 30352 B1 MA30352 B1 MA 30352B1 MA 31321 A MA31321 A MA 31321A MA 31321 A MA31321 A MA 31321A MA 30352 B1 MA30352 B1 MA 30352B1
Authority
MA
Morocco
Prior art keywords
pyrazinones
pyridine
compounds
methods
synthesis
Prior art date
Application number
MA31321A
Other languages
English (en)
Inventor
Robert O Hughes
Andrew Simon Bell
David Graham Brown
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Eric Jon Jacobsen
Todd Michael Maddux
Brent Virgil Mischke
John Major Molyneaux
Joseph Blair Moon
Donald Joseph Rogier Jr
Michael Brent Tollefson
John Keith Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30352B1 publication Critical patent/MA30352B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)

Abstract

Pyridine[3,4-b]pyrazinones Il est décrit des composés et des sels pharmaceutiquement acceptables des composés, lesdits composés ayant la structure de formule I : dans laquelle R2, R6A, R6B et R8 sont tels que définis dans la description. Des compositions pharmaceutiques, méthodes de traitement, procédés de synthèse et intermédiaires correspondants sont également décrits.
MA31321A 2006-04-21 2008-10-21 Pyridine [3,4-b] pyrazinones MA30352B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
MA30352B1 true MA30352B1 (fr) 2009-04-01

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31321A MA30352B1 (fr) 2006-04-21 2008-10-21 Pyridine [3,4-b] pyrazinones

Country Status (42)

Country Link
US (1) US7902195B2 (fr)
EP (1) EP2013208B1 (fr)
JP (1) JP4436892B2 (fr)
KR (1) KR101061328B1 (fr)
CN (1) CN101454320B (fr)
AP (1) AP2408A (fr)
AR (1) AR060525A1 (fr)
AT (1) ATE513831T1 (fr)
AU (1) AU2007242555B2 (fr)
BR (1) BRPI0710658A2 (fr)
CA (1) CA2649775C (fr)
CR (1) CR10327A (fr)
CU (1) CU23777B7 (fr)
CY (1) CY1111739T1 (fr)
DK (1) DK2013208T3 (fr)
DO (1) DOP2007000080A (fr)
EA (1) EA014919B1 (fr)
EC (1) ECSP088803A (fr)
ES (1) ES2366239T3 (fr)
GT (1) GT200700035A (fr)
HK (1) HK1133875A1 (fr)
HR (1) HRP20110539T1 (fr)
IL (1) IL194591A (fr)
MA (1) MA30352B1 (fr)
ME (1) MEP23808A (fr)
MX (1) MX2008012456A (fr)
MY (1) MY148583A (fr)
NL (1) NL2000583C2 (fr)
NO (1) NO20084129L (fr)
NZ (1) NZ571540A (fr)
PA (1) PA8724201A1 (fr)
PE (1) PE20080192A1 (fr)
PL (1) PL2013208T3 (fr)
RS (2) RS51885B (fr)
SI (1) SI2013208T1 (fr)
SV (1) SV2008003074A (fr)
TN (1) TNSN08408A1 (fr)
TW (1) TWI337609B (fr)
UA (1) UA92637C2 (fr)
UY (1) UY30291A1 (fr)
WO (1) WO2007122466A1 (fr)
ZA (1) ZA200808283B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP23808A (en) 2006-04-21 2010-06-10 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones
SI2101777T1 (sl) * 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
PT2247292T (pt) * 2008-03-05 2017-07-17 Merck Patent Gmbh Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes
US20110224250A1 (en) * 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
NZ618135A (en) * 2009-10-26 2015-05-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
TWI542580B (zh) 2010-10-15 2016-07-21 基利科學股份有限公司 治療肺高血壓的組合物及方法
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
WO2013030713A1 (fr) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
JP6425717B2 (ja) 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
CR20160454A (es) 2014-04-01 2016-12-06 Pfizer CROMENO Y 1,1 a,2,7b—TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
SG11201607896YA (en) 2014-04-10 2016-10-28 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (fr) 2014-07-24 2020-01-15 Pfizer Inc Composés de pyrazolopyrimidine
AU2015298378B2 (en) 2014-08-06 2018-08-02 Pfizer Inc. Imidazopyridazine compounds
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
UA125334C2 (uk) 2015-06-17 2022-02-23 Пфайзер Інк. Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
DK3419979T3 (da) 2016-02-23 2020-03-23 Pfizer 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser
WO2018002760A1 (fr) 2016-07-01 2018-01-04 Pfizer Inc. Dérivés de 5,7-dihydro-pyrrolo-pyridine pour le traitement de maladies neurologiques et neurodégénératives
BR112019026955A2 (pt) 2017-06-22 2020-06-30 Pfizer Inc. derivados de di-hidro-pirrolo-piridina
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
TWI801540B (zh) 2018-03-23 2023-05-11 美商輝瑞大藥廠 哌嗪氮雜螺衍生物
EP4297868A4 (fr) 2021-02-23 2025-01-08 Hoth Therapeutics Inc Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
WO2024118524A1 (fr) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Composés d'azaindole et leur utilisation en tant qu'inhibiteurs de phosphodiestérase

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
EP0556393B1 (fr) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Derive de pyrazine fusionnee
TW274550B (fr) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
CN1503797A (zh) * 2001-02-26 2004-06-09 田边制药株式会社 吡啶并嘧啶或二氮杂萘衍生物
WO2002076954A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US20070053831A1 (en) * 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
CA2593005A1 (fr) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes pharmaceutiques constituant des activateurs de caspases et des inducteurs d'apoptose et utilisation de ces composes
CA2608672A1 (fr) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones
KR20080052611A (ko) * 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
WO2007112347A1 (fr) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
MEP23808A (en) 2006-04-21 2010-06-10 Pfizer Prod Inc Pyridine[3,4-b]pyrazinones

Also Published As

Publication number Publication date
MX2008012456A (es) 2008-10-10
CA2649775C (fr) 2011-05-31
ES2366239T3 (es) 2011-10-18
PA8724201A1 (es) 2009-08-26
US7902195B2 (en) 2011-03-08
HRP20110539T1 (hr) 2011-08-31
EP2013208A1 (fr) 2009-01-14
CU20080194A7 (es) 2011-03-21
TW200808794A (en) 2008-02-16
JP2009534368A (ja) 2009-09-24
PL2013208T3 (pl) 2011-10-31
AP2008004640A0 (en) 2008-10-31
MY148583A (en) 2013-04-30
CY1111739T1 (el) 2015-10-07
AR060525A1 (es) 2008-06-25
TNSN08408A1 (fr) 2010-04-14
ATE513831T1 (de) 2011-07-15
TWI337609B (en) 2011-02-21
CR10327A (es) 2008-10-21
GT200700035A (es) 2008-02-05
US20070249615A1 (en) 2007-10-25
AU2007242555A1 (en) 2007-11-01
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
BRPI0710658A2 (pt) 2011-08-16
DK2013208T3 (da) 2011-08-15
SV2008003074A (es) 2010-01-12
CU23777B7 (es) 2012-02-15
JP4436892B2 (ja) 2010-03-24
WO2007122466A1 (fr) 2007-11-01
UY30291A1 (es) 2007-11-30
NL2000583A1 (nl) 2007-10-23
EA014919B1 (ru) 2011-04-29
ZA200808283B (en) 2009-11-25
NZ571540A (en) 2010-10-29
KR20080110930A (ko) 2008-12-19
HK1133875A1 (en) 2010-04-09
AU2007242555B2 (en) 2010-12-16
ECSP088803A (es) 2008-11-27
RS20080484A (en) 2009-07-15
NO20084129L (no) 2008-10-29
KR101061328B1 (ko) 2011-08-31
MEP23808A (en) 2010-06-10
RS51885B (en) 2012-02-29
SI2013208T1 (sl) 2011-09-30
DOP2007000080A (es) 2007-11-15
EA200801998A1 (ru) 2009-04-28
PE20080192A1 (es) 2008-03-01
IL194591A (en) 2012-07-31
EP2013208B1 (fr) 2011-06-22
CA2649775A1 (fr) 2007-11-01
CN101454320A (zh) 2009-06-10
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
TN2009000160A1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoides
NL300929I2 (nl) Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
SE0401971D0 (sv) Piperidne derivatives
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
MA31754B1 (fr) Cis-imidazolines chirales
UY30500A1 (es) Compuestos de azabencimidazolilo
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
EA017278B9 (ru) Соединения азаиндазола и способы применения
TW200738698A (en) Organic compounds
MXPA05012415A (es) Inhibidores de glutamina fructosa-3-fosfato amidotransferasa (gfat).
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
SE0401970D0 (sv) Novel compounds
MA32170B1 (fr) Nouveaux derives d'aminomethylbenzene
WO2006125181A3 (fr) Derives piperidiniques: utilisation comme agents therapeutiques
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
EA200801107A1 (ru) Пиразолы, пригодные для лечения воспалений